Cascade recently announced that the new FXR agonist CS0159, jointly developed by the team of Eric Xu, founder of Shanghai Institute of Medicine, and Li Jia, team of Shanghai Institute of Medicine, is aimed at NASH-CS0159-002 carried out in the United States for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) The Phase II trial (ASCENDER-2) successfully completed the first patient administration.
